Quetiapine levels (CYP3A4)
Quetiapine levels (CYP3A4) is a genetic trait Biome reports in its medication response panel: A rare CYP3A4 poor-metabolizer result was linked to about three times higher quetiapine levels. The DPWG has prescribing guidance for this rare result, but the evidence comes from one pharmacokinetic study with two poor metabolizers and no direct clinical-outcome study.
- Category
- Medication response
- Markers
- CYP3A4 *22 and other validated reduced/no-function alleles
- Strength of evidence
- DPWG guideline; limited pharmacokinetic evidence for rare poor metabolizers
- DNA-test coverage
- Stronger with whole genome
Genes
How Biome reads this
Biome's whole-genome test reads this from one saliva sample, alongside all 3.2 billion letters of your DNA.
Biome DNA test →This page is for educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Genetic results describe tendencies and predispositions, not diagnoses. Always consult a licensed clinician before making decisions about your health, medications, or supplements.